Tatva Chintan Q4 PAT down -17.09% at Rs17.51cr on 31% spike in raw material costs

25 Apr 2022 , 06:59 PM

Tatva Chintan Pharmachem reported -9.33% lower sales revenues yoy for the Mar-22 quarter on consolidated basis at Rs98.53cr.

On a sequential basis, revenues were lower for the quarter by -5.87%. For the full year FY22, the revenues were higher by 44.7% at Rs434cr. Sales got impacted by supply chain constraints.

During the FY22, it complete its Rs.500 crore IPO with the proposed capex investments in Dahej manufacturing facilities and the Vadodara R&D centre only partly utilized. Dividend of Rs.2 per share has been declared.

The consolidated net profit for Q4 was down by -17.09% at Rs17.51cr while the net profits were lower by -23.24% in a sequential basis.

The sharp fall in the net profits can largely attributed to 31% spike in raw material costs despite lower sales. The inventory efficiency gains in the quarter could only partially offset these higher material cost impact.

Net margins stood at 17.77% in Mar-22 quarter compared to 19.43% in Mar-21. The net profit margins were lower by 402 basis points on a sequential basis, compared to Dec-21 quarter.

Financial highlights for Mar-22 compared yoy and sequentially

	Tatva Chintan
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 98.53	₹ 108.67	-9.33%	₹ 104.67	-5.87%
Net Profit (Rs cr)	₹ 17.51	₹ 21.12	-17.09%	₹ 22.81	-23.24%
Diluted EPS (Rs)	₹ 7.90	₹ 10.51		₹ 10.29
Net Margins	17.77%	19.43%		21.79%